IsoPSA prostate cancer diagnostic capabilities-By Adebowale Awosika-Olumo, MD., MS., MPH, PhD., FACE IsoPSA is an innovative blood-based test designed to

Current prostate cancer management By Adebowale Awosika-Olumo, MD., MS., MPH, PhD, FACE Prostate cancer management has rapidly evolved, and integrating

A new UK study suggests “watchful waiting” was no worse than active treatment in lower risk prostate cancers. Buzz Hollander

In this video, Nour Abdallah, MD, discusses new findings on IsoPSA’s prospective predictive ability of clinically significant prostate cancer, presented

The blood-based, non-invasive IsoPSA test is used prior to an initial biopsy to assess the likelihood that a patient has

These days, a new test has been approved for use by the Ministry of Health that makes it possible to

Oct 13, 2022 Cleveland Diagnostics said on Thursday that Medicare administrative contractor CGS Administrators (CGS) has issued a final local coverage

— Clinical Laboratory Meets the Highest Standards in Laboratory Practice — CLEVELAND–(BUSINESS WIRE)–Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing

IsoPSA clinically validated in a study of over 1000 patients and demonstrates significant clinical utility in a study of 900

The use of IsoPSA significantly changed provider behavior, leading to a 55 percent reduction in prostate biopsy recommendations CLEVELAND–(BUSINESS WIRE)–Cleveland